Could a Pre-Surgery immune booster tame brain cancer?

NCT ID NCT07134842

Recruiting now Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing whether giving the immunotherapy drug ipilimumab before standard surgery and chemoradiation is safe and helpful for people with newly diagnosed glioblastoma, an aggressive brain cancer. Sixteen participants will receive up to two doses of ipilimumab before their usual treatment. The study aims to see if the drug can shrink or control the tumor and whether it causes serious side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ipilimumab (an immunotherapy drug)
What this could lead to: If it works, this could point toward a new way to treat glioblastoma by using the immune system before surgery to help control the disease.
What could go wrong: This is a very early, small phase I trial with only 16 people, so results may not apply to everyone. The drug may cause serious side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA - CATEGORY GLIOSARCOMA, ADULT

Contacts and locations

Locations

University College London Hospital
RECRUITING

London, Greater London, NW1 2PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.